At September 30, 2024, Longboard’s cash, cash equivalents and short-term investments were approximately $288.4 million.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Longboard Pharmaceuticals granted Orphan Drug Designation for bexicaserin
- Longboard Pharmaceuticals Inc options imply 0.8% move in share price post-earnings
- Largest borrow rate increases among liquid names
- Longboard Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
- Longboard Pharmaceuticals downgraded to Neutral from Buy at B. Riley